Cardiac diagnostics are undergoing a once-in-a-generation shift. The tools that once lived exclusively inside hospitals are moving into everyday life - transforming how heart disease is detected, managed, and prevented.

This PatentVest Pulse Report maps the convergence of consumer wearables, ambulatory monitors, and traditional 12-lead clinical systems - revealing who is leading, who is catching up, and where the next breakthroughs will occur.  Based on PatentVest’s proprietary analysis, this report identifies the emerging companies shaping the $133 billion cardiac diagnostics market.

Key Insights

• Apple, Samsung, Google, Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, and Masimo have brought heart-rate tracking and single-lead ECGs to hundreds of millions of wrists. Yet all remain confined to rhythm screening - unable to detect ischemia or match 12-lead diagnostic accuracy. 
• Companies such as HeartBeam, iRhythm, and AliveCor are pushing beyond rhythm tracking toward diagnostic-grade performance. HeartBeam stands out as the first to enable clinical-grade ischemia detection tool in credit-card-sized form factor - offering the first credible pathway toward total cardiac intelligence.
• PatentVest’s analysis of 581 patent families across 243 organizations shows traditional device makers like Philips, GE Healthcare, and Nihon Kohden being challenged by next-generation innovators including HeartBeam, AliveCor, Mayo Clinic, Tempus AI, Eko Health, Anumana, Medical AI Co., and Bodyfriend Co.